By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Otonomy, Inc. 

6275 Nancy Ridge Drive
Suite 100
San Diego  California  92121  U.S.A.
Phone: 858-242-5200 Fax: 858-200-0933


SEARCH JOBS

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address diseases of the inner and middle ear. There are no drugs currently approved by the FDA for the lead indications we are currently pursuing for our product candidates. Our lead candidate AuriPro completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and we have submitted a request to the FDA for approval. If approved, we anticipate a commercial launch in early 2016 and are building our business and commercial team to meet the needs of this next stage of our growth.


Key Statistics


Email: info@otonomy.com
Ownership: Public

Web Site: Otonomy
Employees:
Symbol: OTIC
 



Industry
Pharmaceutical






Company News
Otonomy (OTIC) Announces Successful End-Of-Phase II Review By FDA For OTIPRIO In Acute Otitis Media With Tympanostomy Tubes 6/22/2017 10:52:36 AM
Otonomy (OTIC) To Host Key Opinion Leader Meeting For Investors On Ménière's Disease 6/20/2017 10:05:50 AM
Otonomy (OTIC) Reports First Quarter 2017 Financial Results and Provides Corporate Update 5/5/2017 11:42:04 AM
Otonomy (OTIC) To Report First Quarter 2017 Financial Results And Provide Corporate Update 4/28/2017 10:06:53 AM
Otonomy (OTIC) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update 3/3/2017 8:50:26 AM
Otonomy (OTIC) To Report Fourth Quarter And Full Year 2016 Financial Results And Provide Corporate Update 2/24/2017 8:05:29 AM
Otonomy (OTIC) Release: Company Initiates Patient Enrollment In Phase II Clinical Trial Of OTO-104 As Protectant Against Cisplatin-Induced Hearing Loss 1/19/2017 7:08:13 AM
Otonomy (OTIC) Provides Corporate And Product Pipeline Update 1/9/2017 8:08:47 AM
Otonomy (OTIC) Announces Positive Top-Line Results From Phase III Clinical Trial of OTIPRIO in Patients With Acute Otitis Externa 1/5/2017 8:09:14 AM
Otonomy (OTIC) Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer 12/1/2016 7:52:47 AM
123456789
//-->